The ARCoV vaccine, jointly developed by the Academy of Military Medical Sciences , Suzhou Abogen Biosciences and Walvax Biotechnology, is being tested in an international Phase III clinical trial.The country has yet to approve mRNA vaccines developed locally or overseas, but has vaccinated 87.1% of its population using several domestically developed shots based on other technologies.
The neutralising antibody level against Omicron showed a 47-fold reduction compared with the level against a “wild-type”that contains no major mutations, said the paper published on Monday. “Our data presented here clearly demonstrate that a third dose of ARCoV would probably lead to a sharp increase in neutralisation antibodies not only against the WT SARS-CoV-2 but also the newly Omicron variant,” the study said.
The researchers said they also conducted animal tests on two new mRNA vaccine candidates targeting Omicron and the result showed that the induced antibody levels were comparable to those elicited by the original ARCoV.
Their problem is.. we're not animals.
My children crying themselves to sleep because they sleep hungry cripples me as a man. Not knowing where your next meal will come from is heartbreaking. I ask for any food nearing their expiry date or mealie meal. Just so my children can eat 🙏🏻😭